Brian's profile was created using:
Sort By:

1-10 of 35 online sources for Brian Daniels

  • View Online Source
    www.dailylead.com/servlet/rss?b=BIO - [Cached Version]
    Published on: 10/12/2008    Last Visited: 11/29/2007  

    Speakers include Roche CEO George Abercrombie; new Pfizer R&D head Martin Mackay; & Brian Daniels, Bristol-Myers' head of development.

  • View Online Source
    www.sec.gov/Archives/edgar/data/1428698/0001225208-08-0 - [Cached Version]
    Published on: 10/6/2008    Last Visited: 10/7/2008  

    0001428698 DANIELS BRIAN 345 PARK AVENUE NEW YORK NY 10154 1 SVP Global Development

  • View Online Source
    investor.bms.com/phoenix.zhtml?c=106664&p=irol-newsArti - [Cached Version]
    Published on: 3/17/2008    Last Visited: 7/24/2008  

    Brian Daniels, M.D., senior vice president, Global Development, will make a formal presentation about the company at 1:45 p.m. ET today.

    Bristol-Myers Squibb will also present at the Lehman Brothers Global Healthcare Conference on Wednesday, March 19, 2008.

  • View Online Source
    www.squibb.com/aboutbms/corporate_governance/executive_ - [Cached Version]
    Published on: 6/17/2008    Last Visited: 6/17/2008  

    , BMS.com Home , About Us , Corporate Governance , Brian Daniels, M.D.

    Brian Daniels, M.D.

    Senior Vice President, Global Development, R&D

    Brian Daniels, M.D., is senior vice president, Global Development, and a member of the Management Council, the company's most senior leadership group.

    Daniels was appointed senior vice president, Global Clinical Development in December 2004.He has responsibility for developing and executing strategies to ensure the rigorous and efficient development of commercially significant product opportunities globally.

    Daniels joined Bristol-Myers Squibb in July 2000 as vice president ofthe Immunology, Pulmonary, and Dermatology therapeutic area, where he provided strategic oversight and led the early development of compounds including Orencia and belatacept.

    In 2002, Daniels was promoted to vice president, Full Development, providing leadership to the development of six key clinical programs including Reyataz and Baraclude.Daniels also led efforts to improve productivity and to standardize and integrate the global execution of clinical trials as vice president of Global Development Operations.

    Prior to joining Bristol-Myers Squibb, Daniels spent four years at Merck Research Laboratories in clinical research where he ultimately assumed the role of senior director, Pulmonary and Immunology.He has also worked in clinical research at Genentech.

    Daniels holds bachelor's and master's degrees in biology from the Massachusetts Institute of Technology and a medical degree from Washington University School of Medicine.He received training in internal medicine at New York Hospital and in Rheumatology at the University of California in San Francisco.

  • View Online Source
    www.interwest.com/news/portfolio/bioworldtoday_0508.htm - [Cached Version]
    Published on: 5/14/2008    Last Visited: 8/28/2008  

    While restoring blood flow, either through the use of thrombolytic drugs or surgical intervention such as angioplasty or implanting a stent, improves clinical outcomes in heart attack patients, it can cause significant injury to heart tissues, referred to as reperfusion injury, explained Brian Daniels, senior vice president of global development and medical affairs for BMS.

    Currently there are no "appropriate therapeutics" available to treat reperfusion injury, which Daniels called "a high unmet medical need."

    However, he told BioWorld Today, KAI's product is promising.

    "The science at KAI in the protein kinase C field is really spectacular," he said."They have dissected out tissue specificities that I think really will allow us to test this hypothesis clinically."

    KAI, Daniels added, has "advanced the science significantly, both in the understanding of how to selectively target certain protein kinase C isoenzymes so it is tissue specific and also how to deliver those to the cells at the time it is needed."

    Having a product like KAI -9803 that can "positively advance the standard of care" not only will benefit cardiac patients and their physicians, but also will benefit health care payers because of better long-term outcomes, he said.

    Daniels called his firm's deal with KAI part of BMS's "string of pearls" strategy.

    "It totally aligns to our strategy of looking at a diverse range of options to bring in additional investigational compounds to Bristol-Myers Squibb," he said.

    While BMS has a long history of developing and commercializing cardiovascular medications, such as Pravachol (pravastatin sodium) and Plavix (clopidogrel bisulfate), "you can't do everything inside the four walls of your company," Daniels said.

    "A good biopharma company who really wants to be 21st century is constantly looking for additional opportunities to enrich their pipeline," he said.

  • View Online Source
    www.glucophagexr.com/aboutbms/corporate_governance/exec - [Cached Version]
    Published on: 7/6/2008    Last Visited: 7/6/2008  

    , BMS.com Home , About Us , Corporate Governance , Brian Daniels, M.D.

    Brian Daniels, M.D.

    Senior Vice President, Global Development & Medical Affairs
    ...
    Brian Daniels, M.D.Brian Daniels is senior vice president, Global Development and Medical Affairs, and a member of the Management Council, the company's most senior leadership group.In this position, he helps drive the company's focus on science and medicine as a central strategy of our next-generation BioPharma vision.

    "Pharmaceutical R&D is a long and complex process," says Brian."My role is to make the internal workings as simple as possible so that good, bright people can make substantial contributions to patient care.Our goal is to produce medicines that change the standard of care in a meaningful way for physicians, provide economic value to payers and, most importantly, extend and enhance the lives of patients."

    Brian joined Bristol-Myers Squibb in 2000 as vice president of the Immunology, Pulmonary, and Dermatology therapeutic area, where he provided strategic oversight and led the early development of compounds including ORENCIA and belatacept.

    In 2002, Brian was promoted to vice president, Full Development, providing leadership to the development of six key clinical programs including REYATAZ and BARACLUDE.He also led efforts to improve productivity and to standardize and integrate the global execution of clinical trials as vice president of Global Development Operations.He was appointed senior vice president, Global Clinical Development in 2004, and to his current position in March 2008.

    Prior to joining Bristol-Myers Squibb, Brian spent four years at Merck Research Laboratories in clinical research, where he held the role of senior director, Pulmonary and Immunology.He has also worked in clinical research at Genentech.

    Brian is married and has a son, 18, and a daughter, 16.Next to spending time with his family, what he enjoys most is gardening."It's sort of like simplified drug development," he says."It takes a lot of careful tending to develop a great garden.But when you're successful, it's a beautiful thing."

    Brian holds bachelor's and master's degrees in biology from the Massachusetts Institute of Technology and a medical degree from Washington University School of Medicine.He received training in internal medicine at New York Hospital and in rheumatology at the University of California in San Francisco.

  • View Online Source
    www.sec.gov/Archives/edgar/data/14272/0000014272-08-000 - [Cached Version]
    Published on: 3/7/2008    Last Visited: 8/9/2008  

    0001428698 DANIELS BRIAN BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCELINE ROAD PRINCETON NJ 08543 0 1 0 0 SVP Global Development

  • View Online Source
    www.sec.gov/Archives/edgar/data/1428698/0000014272-08-0 - [Cached Version]
    Published on: 3/11/2008    Last Visited: 3/12/2008  

    0001428698 DANIELS BRIAN BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCELINE ROAD PRINCETON NJ 08543 0 1 0 0 SVP Global Development

  • View Online Source
    investor.bms.com/phoenix.zhtml?c=106664&p=irol-newsArti - [Cached Version]
    Published on: 6/13/2008    Last Visited: 10/5/2008  

    "Bristol-Myers Squibb is committed to helping patients in their fight against rheumatoid arthritis," said Brian Daniels, M.D., rheumatologist and senior vice president, Global Development & Medical Affairs, Bristol-Myers Squibb.

  • View Online Source
    loanfirestate.blogvsop.com/2008/05/18/analysts-said-the - [Cached Version]
    Published on: 5/1/2008    Last Visited: 5/27/2008  

    While restoring blood flow, either through the use of thrombolytic drugs or surgical intervention such as angioplasty or implanting a stent, improves clinical outcomes in heart attack patients, it can cause significant injury to heart tissues, referred to as reperfusion injury, explained Brian Daniels, senior vice president of global development and medical affairs for BMS.

Page:  1 2 3 4 Next

Wrong Person?

Try these instead
More...
For Recruiters For Sales Pros

Copyright © 2008 Zoom Information Inc. All rights reserved.

BPS_S5.0.5_newui_RC002_P001.1 OM17